Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 75INDUSTRY 13NIH 3FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1Breast 1

Conditions

Uveal Melanoma 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Melanoma 1Fallopian Tube Neoplasms 1

Interventions

Cyclophosphamide 385Specimen Handling 370Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Interventional × poly ICLC × Clear all
NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03206047 2025-03-13

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
12 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02129075 2021-11-16

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled 13 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡